Keytruda + chemo reduces risk of death by one-third vs. chemo as first-line treatment for persistent, recurrent, or metastatic cervical cancer

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models.